FibroGen (FGEN) Tops Q4 EPS by 30c

FibroGen (NASDAQ: FGEN) reported Q4 EPS of $0.23, $0.30 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $108.1 million versus the consensus estimate of $72.1 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.

You May Also Be Interested In

• Verizon to cut 3,000 jobs as it shifts stores to franchises
• Abbott beats second-quarter estimates, raises 2026 guidance
• Private Bancorp of America, Inc. (PBAM) Tops Q2 EPS by 26c